Bioventus 8-K Signals Leadership/Comp Changes on Jan 9
Ticker: BVS · Form: 8-K · Filed: Jan 12, 2024 · CIK: 1665988
Complexity: simple
Sentiment: neutral
Topics: executive-changes, corporate-governance, compensation
TL;DR
**Bioventus filed an 8-K about officer/director changes and pay, watch for details!**
AI Summary
Bioventus Inc. filed an 8-K on January 12, 2024, reporting an event that occurred on January 9, 2024, related to the departure or election of directors or officers and their compensatory arrangements. This filing indicates potential changes in leadership or executive compensation, which could impact the company's strategic direction and financial performance. Investors should pay attention to subsequent filings for details on who departed or was elected, and the specifics of any new compensation packages, as these can influence investor confidence and future stock valuation.
Why It Matters
Changes in executive leadership or compensation can signal shifts in company strategy, financial health, or governance, directly affecting investor perception and stock value.
Risk Assessment
Risk Level: medium — Without specific names or details on the changes, there's uncertainty regarding the impact on company stability and future performance.
Analyst Insight
A smart investor would monitor for subsequent filings (like a 10-K or 10-Q, or another 8-K) that provide specific names, roles, and compensation details related to these reported changes to assess their potential impact on company strategy and performance.
Key Players & Entities
- Bioventus Inc. (company) — the registrant filing the 8-K
- January 9, 2024 (date) — date of the earliest event reported
- January 12, 2024 (date) — date the 8-K was filed
- 001-37844 (other) — Commission File Number for Bioventus Inc.
- BVS (other) — Trading Symbol for Bioventus Inc. Class A common Stock
- The Nasdaq Global Select Market (other) — exchange where Bioventus Inc. Class A common Stock is registered
FAQ
What was the specific event reported in this 8-K filing by Bioventus Inc.?
The 8-K filing by Bioventus Inc. reported an event concerning the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' that occurred on January 9, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 12, 2024, as indicated by the 'FILED AS OF DATE' and 'ACCESSION NUMBER' information.
What is the trading symbol and exchange for Bioventus Inc.'s Class A common Stock?
Bioventus Inc.'s Class A common Stock trades under the symbol 'BVS' on 'The Nasdaq Global Select Market', as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address of Bioventus Inc. as listed in the filing?
The business address of Bioventus Inc. is 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, with a business phone number of (919) 474-6700.
Does this 8-K filing provide specific names of the officers or directors involved in the reported changes?
No, this 8-K filing, as provided, only indicates the *category* of event ('Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers') but does not specify the names of the individuals involved or the details of their arrangements.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-01-12 17:10:52
Key Financial Figures
- $0.001 — which registered Class A common Stock, $0.001 par value per share BVS The Nasdaq
Filing Documents
- d727616d8k.htm (8-K) — 22KB
- 0001193125-24-007640.txt ( ) — 144KB
- bvs-20240109.xsd (EX-101.SCH) — 3KB
- bvs-20240109_lab.xml (EX-101.LAB) — 18KB
- bvs-20240109_pre.xml (EX-101.PRE) — 11KB
- d727616d8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 9, 2024, the Board of Directors (the "Board") of Bioventus Inc. (the "Company") approved the acceleration of vesting of all of the outstanding and unvested equity awards (the "Equity Awards") of Anthony P. Bihl III, the Company's then Interim President and Chief Executive Officer and a director on the Board, effective immediately. The Equity Awards, which were granted in connection with Mr. Bihl's appointment as the Company's Interim President and Chief Executive Officer in April 2023, were to vest in April 2024, subject to continued employment, and provided for acceleration of vesting at the discretion of the Board and/or the Board's Compensation Committee. As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024. The Board's decision to accelerate the outstanding and unvested Equity Awards pursuant to their terms was based on Mr. Bihl's performance and contributions to the Company.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOVENTUS INC. Date: January 12, 2024 By: /s/ Anthony D'Adamio Anthony D'Adamio Senior Vice President and General Counsel